Real-Time Monitoring for Improving Cancer Diagnosis and Prognosis
For deadly cancers, which are difficult to successfully treat after tumor metastasis, identification of useful prognostic and predictive biomarkers for informing clinicians early during treatment of the need to revise treatments for patients is expected to improve treatment outcomes. Real- time monitoring of cancers during treatment will allow early detection of minimal residual disease and the presence of tumor heterogeneity, which need to be addressed for successful long-term treatment success. Liquid biopsies allow non-invasive serial timepoint assessment of a patient’s treatment status. Detection of circulating tumor DNA and circulating tumor cells are now reported for different cancers that herald their usefulness in cancer screening and treatment decisions. Detection of key drug-targetable mutations early during the progression of the cancer can provide better alternatives for patient treatment. This Special Issue highlights recent approaches for addressing improving patient outcomes via real-time monitoring of cancer patients during therapy to identify earlier timepoints for clinical decisions on long-term treatment.
Prof. Dr. Maria Li Lung
Dr. Josephine Ko
- cancer biomarkers
- liquid biopsies
- circulating tumor cell
- real-time monitoring
|Journal Name||Impact Factor||CiteScore||Launched Year||First Decision (median)||APC|
|-||-||2021||16.6 Days||CHF 1000||Submit|
|5.2||7.4||2009||18.2 Days||CHF 2900||Submit|
|2.6||2.6||1994||18.4 Days||CHF 2200||Submit|
|3.6||3.6||2011||18.8 Days||CHF 2600||Submit|
|2.8||2.7||2013||21.7 Days||CHF 2700||Submit|
Preprints is a platform dedicated to making early versions of research outputs permanently available and citable. MDPI journals allow posting on preprint servers such as Preprints.org prior to publication. For more details about reprints, please visit https://www.preprints.org.